SNPX vs. AFMD, PIRS, FNCH, BCTX, SNTI, NKGN, NNVC, SYBX, COEP, and IPA
Should you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Affimed (AFMD), Pieris Pharmaceuticals (PIRS), Finch Therapeutics Group (FNCH), BriaCell Therapeutics (BCTX), Senti Biosciences (SNTI), NKGen Biotech (NKGN), NanoViricides (NNVC), Synlogic (SYBX), Coeptis Therapeutics (COEP), and ImmunoPrecise Antibodies (IPA). These companies are all part of the "pharmaceutical products" industry.
Synaptogenix vs.
Affimed (NASDAQ:AFMD) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.
In the previous week, Affimed's average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score.
Affimed has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.
30.8% of Affimed shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 3.8% of Affimed shares are held by insiders. Comparatively, 2.7% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Synaptogenix has lower revenue, but higher earnings than Affimed.
Affimed currently has a consensus price target of $13.50, suggesting a potential upside of 1,084.21%. Synaptogenix has a consensus price target of $14.00, suggesting a potential upside of 316.67%. Given Affimed's higher probable upside, equities research analysts plainly believe Affimed is more favorable than Synaptogenix.
Affimed received 437 more outperform votes than Synaptogenix when rated by MarketBeat users. Likewise, 70.24% of users gave Affimed an outperform vote while only 66.67% of users gave Synaptogenix an outperform vote.
Synaptogenix has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Synaptogenix's return on equity of -42.14% beat Affimed's return on equity.
Summary
Affimed beats Synaptogenix on 8 of the 13 factors compared between the two stocks.
Get Synaptogenix News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Synaptogenix Competitors List
Related Companies and Tools
This page (NASDAQ:SNPX) was last updated on 1/22/2025 by MarketBeat.com Staff
